Open an account

Enovis

ENOV · NYSE

$20.69+$0.82 (+4.13%)TodayMarket closed ·
Prev close $19.87

About ENOV

Enovis Corp. operates as a medical technology growth company. The company is headquartered in Wilmington, Delaware and currently employs 7,802 full-time employees. The company went IPO on 2008-05-08. The company is focused on developing clinically differentiated solutions by manufacturing and distributing high-quality medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. The company operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative diseases. The Prevention & Recovery products are marketed under several brand names, such as DJO. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. The company also operates a Enovis Growth eXcellence business system (EGX).

Employees
7,802
Headquarters
Wilmington, Delaware
Listed
May 8, 2008
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
enovis.com

ENOV key statistics

Market cap
1.15B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.50M
Volume
1.19M
Open price
$20.16
High today
$20.89
Low today
$19.89
52 Week high
$34.28
52 Week low
$16.70

Enovis (ENOV) at a glance

As of Oct 20, 2026, Enovis (ENOV) shares are priced at $20.69, giving the company a market cap of 1.15B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $19.89 and $20.89. The current price is 4.0% above the day's low and 1.0% below its high.

Volume so far is 1.19M shares, below the average of 1.50M shares a day.

Over the past year Enovis has ranged from $16.70 to $34.28, and now sits 23% of the way up that range.

Enovis met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported $0.90 per share against an estimate of $0.8656.

The average analyst price target is $40.43, 95.4% above the current price, from 10 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 10 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 14 analystsAvg $40.43
Low
$27.27
Now
$20.69
High
$54.60

ENOV earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 9.2% on average.

  1. Q3 FY24: reported $0.73 per share against an estimate of $0.628
  2. Q4 FY24: reported $0.98 per share against an estimate of $0.9336
  3. Q1 FY25: reported $0.81 per share against an estimate of $0.7584
  4. Q2 FY25: reported $0.79 per share against an estimate of $0.7331
  5. Q3 FY25: reported $0.75 per share against an estimate of $0.6617
  6. Q4 FY25: reported $0.95 per share against an estimate of $0.8384
  7. Q1 FY26: reported $0.89 per share against an estimate of $0.833
  8. Q2 FY26: reported $0.90 per share against an estimate of $0.8656

ENOV news

  • Press releasePRNewswire

    Enovis becomes first multi-registry industry sponsor of AAOS Registry Program

  • Press releasePRNewswire

    eCential Robotics Announces Binding Offer from Enovis

  • Press releaseBusiness Wire

    Knoa Pharma Begins Operations as a New, Public Health-Focused Company Dedicated to Supporting Patients and Abating the Opioid Crisis

  • Vandana Singh

    Analyst Backs Enovis On Cash Flow Turnaround

  • 4 Analysts Assess Enovis: What You Need To Know

  • Earnings Scheduled For November 6, 2025

  • Assessing Enovis: Insights From 4 Financial Analysts

  • Where Enovis Stands With Analysts

Similar companies

Companies in the same industry as Enovis

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.